GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Pharmaceuticals Inc (NAS:FUSN) » Definitions » Cash-to-Debt

Fusion Pharmaceuticals (Fusion Pharmaceuticals) Cash-to-Debt : 4.64 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Fusion Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Fusion Pharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2023 was 4.64.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Fusion Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Fusion Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

FUSN' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.25   Med: 5014.94   Max: No Debt
Current: 4.64

During the past 7 years, Fusion Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 4.25. And the median was 5014.94.

FUSN's Cash-to-Debt is ranked worse than
56.21% of 1539 companies
in the Biotechnology industry
Industry Median: 6.54 vs FUSN: 4.64

Fusion Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Fusion Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Fusion Pharmaceuticals Cash-to-Debt Chart

Fusion Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial No Debt No Debt 29.87 4.25 4.64

Fusion Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.25 4.19 3.91 3.64 4.64

Competitive Comparison of Fusion Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Fusion Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fusion Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Fusion Pharmaceuticals's Cash-to-Debt falls into.



Fusion Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Fusion Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Fusion Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fusion Pharmaceuticals  (NAS:FUSN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Fusion Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Fusion Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Fusion Pharmaceuticals (Fusion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
270 Longwood Road South, Hamilton, ON, CAN, L8P 0A6
Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others.
Executives
Teresa Marie Bitetti director 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jeremy Bender director 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
David D. Meek director 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Dmitri Bobilev officer: Chief Medical Officer C/O FUSION PHARMACEUTICALS INC., 270 LONGWOOD RD. SOUTH, HAMILTON Z4 L8P 0A6
Steven Gannon director C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8
John Valliant director, officer: Chief Executive Officer FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON A6 L8P 0A6
Christopher P Leamon officer: Chief Scientific Officer C/O FUSION PHARMACEUTICALS INC., 2 INTERNATIONAL PLACE SUITE 2310, BOSTON MA 02110
Mohit Rawat officer: President and CBO FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P 0A6
Donald A Bergstrom director 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Philina Lee director C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6
Adams Street Partners Llc 10 percent owner ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
John J Crowley officer: Chief Financial Officer 251 BALLARDVALE STREET, WILMINGTON MA 01887
Healthcap Vii, L.p. 10 percent owner 18 AVENUE D'OUCHY, CH 1006 LAUSANNE V8 1000-1018
James J O'leary officer: Chief Medical Officer 830 WINTER STREET, WALTHAM MA 02452